The continued spread of the SARS-CoV-2 virus has spawned a Greek alphabet of variants - a naming system used by the World Health Organization to track concerning new mutations of the virus that causes COVID-19. Some have equipped the virus with better ways of infecting humans or evading vaccine protection.
The Delta variant first detected in India remains the most worrisome. It is striking unvaccinated populations in many countries and has proven capable of infecting a higher proportion of vaccinated people than its predecessors.
The WHO classifies Delta as a variant of concern, meaning it has been shown capable of increasing transmissibility, causing more severe disease or reducing the benefit of vaccines and treatments.
According to Shane Crotty, a virologist at the La Jolla Institute for Immunology in San Diego, Delta’s “superpower” is its transmissibility.
Chinese researchers found that people infected with Delta carry 1,260 times more virus in their noses compared with the original version of the coronavirus. Some US research suggests that the “viral load” in vaccinated individuals who become infected with Delta is on par with those who are unvaccinated, but more research is needed.
While the original coronavirus took up to seven days to cause symptoms, Delta can cause symptoms two to three days faster, giving the immune system less time to respond and mount a defense.
Delta also appears to be mutating further, with reports emerging of a “Delta Plus” variant, a sub-lineage that carries an additional mutation that has been shown to evade immune protection.
India listed Delta Plus as a variant of concern in June, but neither the US Centers For Disease Control and Prevention nor the WHO have done so yet. According to Outbreak.info, an open-source COVID-19 database, Delta Plus has been detected in at least 32 countries. Experts say it is not yet clear whether it is more dangerous.
Lambda- on the wane?
The Lambda variant has attracted attention as a potential new threat. But this version of the coronavirus, first identified in Peru in December, may be receding, several infectious disease experts told Reuters.
The WHO classifies Lambda as a variant of interest, meaning it carries mutations suspected of causing a change in transmissibility or causing more severe disease, but it is still under investigation. Lab studies show it has mutations that resist vaccine-induced antibodies.
Dr. Eric Topol, a professor of molecular medicine and director of the Scripps Research Translational Institute in La Jolla, California, said the percentage of new Lambda cases reported to GISAID, a database that tracks SARS-CoV-2 variants, has been dropping, a sign that the variant is waning.
In a recent call with the CDC, disease experts said Lambda did not appear to be causing increased transmissibility, and vaccines appear to be holding up well against it, said Dr. William Schaffner, an infectious diseases expert at Vanderbilt University Medical Center who attended the discussion.
B.1.621 – One to watch
The B.1.621 variant, which first arose in Colombia in January, where it caused a major outbreak, has yet to earn a Greek letter name.
The European Center for Disease Prevention and Control has listed it as a variant of interest, while Public Health England describes B.1.621 as a variant under investigation. It carries several key mutations, including E484K, N501Y and D614G, that have been linked with increased transmissibility and reduced immune protection.
So far, there have been 37 likely and confirmed cases in the UK, according to a recent government report, and the variant has been identified in a number of patients in Florida.
More on the way?
Dr. Anthony Fauci, the White House’s chief medical adviser, recently warned that the United States could be in trouble unless more Americans get vaccinated, as a large pool of unvaccinated people give the virus more opportunity to spread and mutate into new variants.
Proponents of greater international distribution of vaccine doses by rich countries say the same thing could happen as variants emerge unchecked among the populations of poor nations where very few people have been inoculated.
Even so, a key issue is that the current vaccines block severe disease but do not prevent infection, said Dr. Gregory Poland, a vaccine scientist at the Mayo Clinic. That is because the virus is still capable of replicating in the nose, even among vaccinated people, who can then transmit the disease through tiny, aerosolized droplets.
To defeat SARS-CoV-2, he said, will likely require a new generation of vaccines that also block transmission. Until then, the world will remain vulnerable to the rise of new coronavirus variants, according to Poland and other experts.
US officials divided over mask rules for schools as child COVID hospitalizations riseThe indecision for facemask requirements for schools is deepening in the United States as officials spar on how to approach the matter as the delta ... Coronavirus
COVID-19: Transparent facemasks are becoming part of the new normalThe COVID-19 pandemic has focused our attention on facemasks like never before. At Alder Hey Children’s Hospital we are lucky to have an Innovation ... Opinion
Australia’s Delta COVID-19 outbreak continues as vaccination push ramps upAustralia continued its struggle to contain a delta outbreak across the nation’s east coast, with the race to increase vaccinations now key to ... Coronavirus
Germany’s COVID-19 vaccine campaign prevented 38,000 deaths, 706,000 cases: StudyGermany’s mass COVID-19 vaccination campaign has prevented 38,000 deaths in the last six months and a half, according to a study by the country’s ... Coronavirus